Systemic lupus erythematosus, N. Engl. J. Med, vol.365, pp.2110-2121, 2011. ,
Understanding the epidemiology and progression of systemic lupus erythematosus, Semin. Arthritis Rheum, vol.39, pp.257-268, 2010. ,
Taming lupus-a new understanding of pathogenesis is leading to clinical advances, Nat. Med, vol.18, pp.871-882, 2012. ,
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood, J. Exp. Med, vol.197, pp.711-723, 2003. ,
Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment, Lancet, vol.382, pp.809-818, 2013. ,
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, Lancet, vol.377, pp.721-731, 2011. ,
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, Arthritis Rheum, vol.63, pp.3918-3930, 2011. ,
Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus, Arthritis Rheum, vol.60, pp.1785-1796, 2009. ,
Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosageescalation study, Arthritis Rheum, vol.62, pp.542-552, 2010. ,
CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene, J. Immunol, vol.150, pp.5445-5456, 1993. ,
IL17Family cytokines and the expanding diversity of effector T cell lineages, Annu. Rev. Immunol, vol.25, pp.821-852, 2007. ,
Structure and signalling in the IL-17 receptor family, Nat. Rev. Immunol, vol.9, pp.556-567, 2009. ,
Act1, a U-box E3 ubiquitin ligase for IL-17 signaling, Sci. Signal, vol.2, p.63, 2009. ,
IL-17 enhances chemokine gene expression through mRNA stabilization, J. Immunol, vol.179, pp.4135-4141, 2007. ,
IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential, Clin. Sci, vol.122, pp.487-511, 2012. ,
The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation, Nat. Immunol, vol.12, pp.844-852, 2011. ,
Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF), Nat. Immunol, vol.12, pp.853-860, 2011. ,
The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin, Annu. Rev. Pathol, vol.8, pp.477-512, 2013. ,
Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I, J. Exp. Med, vol.207, pp.291-297, 2010. ,
Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity, Science, vol.332, pp.65-68, 2011. ,
Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis, J. Exp. Med, vol.208, pp.1635-1648, 2011. ,
An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis, Immunity, vol.39, pp.676-686, 2013. ,
Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3, J. Exp. Med, vol.205, pp.1551-1557, 2008. ,
T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines, J. Exp. Med, vol.183, pp.2593-2603, 1996. ,
,
, effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages, vol.6, pp.1123-1132, 2005.
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17, Nat. Immunol, vol.6, pp.1133-1141, 2005. ,
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17 + T helper cells, Cell, vol.126, pp.1121-1133, 2006. ,
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells, Nature, vol.441, pp.235-238, 2006. ,
Transforming growth factor-beta induces development of the T(H)17 lineage, Nature, vol.441, pp.231-234, 2006. ,
TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells, Immunity, vol.24, pp.179-189, 2006. ,
A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses, Nat. Immunol, vol.9, pp.650-657, 2008. ,
The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo, Nat. Immunol, vol.10, pp.314-324, 2009. ,
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain, Nature, vol.421, pp.744-748, 2003. ,
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation, J. Exp. Med, vol.201, pp.233-240, 2005. ,
Divergent pro-and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation, J. Exp. Med, vol.198, pp.1951-1957, 2003. ,
TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology, Nat. Immunol, vol.8, pp.1390-1397, 2007. ,
Control of TH17 cells occurs in the small intestine, Nature, vol.475, pp.514-518, 2011. ,
Pathogen-induced human TH17 cells produce IFN-? or IL-10 and are regulated by IL-1?, Nature, vol.484, pp.514-518, 2012. ,
The encephalitogenicity of T(H)17 cells is dependent on IL-1-and IL-23-induced production of the cytokine GM-CSF, Nat. Immunol, vol.12, pp.568-575, 2011. ,
ROR?t drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation, Nat. Immunol, vol.12, pp.560-567, 2011. ,
Induction and molecular signature of pathogenic TH17 cells, Nat. Immunol, vol.13, pp.991-999, 2012. ,
Fate mapping of IL-17-producing T cells in inflammatory responses, Nat. Immunol, vol.12, pp.255-263, 2011. ,
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides, J. Exp. Med, vol.203, pp.2271-2279, 2006. ,
IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not, J. Mol. Med, vol.87, pp.523-536, 2009. ,
Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A, J. Exp. Med, vol.207, pp.1293-1305, 2010. ,
The many faces of Th17 cells, Curr. Opin. Immunol, vol.23, pp.702-706, 2011. ,
Innate IL-17-producing cells: the sentinels of the immune system, Nat. Rev. Immunol, vol.10, pp.479-489, 2010. ,
IL-17-producing ?? T cells and innate lymphoid cells, Eur. J. Immunol, vol.42, pp.2221-2231, 2012. ,
The role of IL-17-secreting mast cells in inflammatory joint disease, Nat. Rev. Rheumatol, vol.9, pp.375-379, 2013. ,
IL-23 induces spondyloarthropathy by acting on ROR-?t + CD3 + CD4-CD8-entheseal resident T cells, Nat. Med, vol.18, pp.1069-1076, 2012. ,
Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response, Arthritis Res. Ther, vol.13, p.95, 2011. ,
Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis, Arthritis Rheum, vol.64, pp.99-109, 2012. ,
Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive ?/? T cells in patients with active ankylosing spondylitis, Arthritis Rheum, vol.64, pp.1420-1429, 2012. ,
Analysis of interleukin-23 receptor (IL23R) gene polymorphisms in systemic lupus erythematosus, Tissue Antigens, vol.70, pp.233-237, 2007. ,
No association between interleukin 23 receptor gene polymorphisms and systemic lupus erythematosus, Rheumatol. Int, vol.30, pp.33-38, 2009. ,
The genetics of systemic lupus erythematosus and implications for targeted therapy, Ann. Rheum. Dis, vol.70, pp.37-43, 2011. ,
Copy number variations of interleukin-17 F, interleukin-21, and interleukin-22 are associated with systemic lupus erythematosus, Arthritis Rheum, vol.63, pp.3487-3492, 2011. ,
Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity, Clin. Immunol, vol.127, pp.385-393, 2008. ,
Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus, Ann. Rheum. Dis, vol.68, pp.604-606, 2009. ,
Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity, J. Clin. Immunol, vol.30, pp.221-225, 2010. ,
Increased serum interleukin 17 in patients with systemic lupus erythematosus, Mol. Biol. Rep, vol.37, pp.81-85, 2010. ,
IL-17 in cutaneous lupus erythematosus, Eur. J. Intern. Med, vol.21, pp.202-207, 2010. ,
Clinical associations of serum interleukin-17 in systemic lupus erythematosus, Arthritis Res. Ther, vol.15, p.97, 2013. ,
Th22, but not Th17 might be a good index to predict the tissue involvement of systemic lupus erythematosus, J. Clin. Immunol, vol.33, pp.767-774, 2013. ,
Increased interleukin-17 production in patients with systemic sclerosis, Arthritis Rheum, vol.43, pp.2455-2463, 2000. ,
Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys, J. Immunol, vol.181, pp.8761-8766, 2008. ,
Th17 and natural Treg cell population dynamics in systemic lupus erythematosus, Arthritis Rheum, vol.60, pp.1472-1483, 2009. ,
Expression of interleukin-17 is correlated with interferon-? expression in cutaneous lesions of lupus erythematosus, Clin. Exp. Dermatol, vol.36, pp.512-520, 2011. ,
Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus, Arthritis Res. Ther, vol.12, p.53, 2010. ,
, Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus, vol.141, pp.197-204, 2011.
Elevated Th17 cells are accompanied by FoxP3 + Treg cells decrease in patients with lupus nephritis, Rheumatol. Int, vol.32, pp.949-958, 2012. ,
Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells, Nat. Immunol, vol.8, pp.639-646, 2007. ,
Decreased serum IL-22 levels in patients with systemic lupus erythematosus, Clin. Chim. Acta Int. J. Clin. Chem, vol.401, pp.179-180, 2009. ,
IL-22 + CD4+ T-cells in patients with active systemic lupus erythematosus, Exp. Biol. Med. (Maywood), pp.193-199, 2013. ,
Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells, Nat. Immunol, vol.10, pp.857-863, 2009. ,
Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells, Nat. Immunol, vol.10, pp.864-871, 2009. ,
IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine, Nature, vol.491, pp.259-263, 2012. ,
Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid, Mucosal Immunol, vol.7, pp.101-113, 2013. ,
T cell receptor alpha/ beta expressing double-negative (CD4-/CD8-) and CD4 + T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis, J. Immunol, vol.143, pp.103-112, 1989. ,
Human TCR-alpha beta+ CD4-CD8-T cells can derive from CD8+ T cells and display an inflammatory effector phenotype, J. Immunol, vol.183, pp.4675-4681, 2009. ,
Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus, J. Immunol, vol.166, pp.4216-4222, 2001. ,
CAMP response element modulator a expression in patients with systemic lupus erythematosus, Lupus, vol.15, pp.840-844, 2006. ,
cAMP-responsive element modulator ? (CREM?) trans-represses the transmembrane glycoprotein CD8 and contributes to the generation of CD3 + CD4-CD8-T cells in health and disease, J. Biol. Chem, vol.288, pp.31880-31887, 2013. ,
cAMP responsive element modulator (CREM)? mediates chromatin remodeling of CD8 during the generation of CD3+CD4-CD8-T cells, J. Biol. Chem, vol.288, pp.1880-1887, 2013. ,
Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis, Clin. Exp. Immunol, vol.159, pp.1-10, 2010. ,
Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation, Nat. Med, vol.13, pp.1173-1175, 2007. ,
Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus, J. Immunol, vol.187, pp.538-552, 2011. ,
Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis, J. Immunol, vol.147, pp.117-123, 1991. ,
Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus, J. Exp. Med, vol.202, pp.1131-1139, 2005. ,
Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus, Science, vol.294, pp.1540-1543, 2001. ,
Human plasmacytoid dendritic cells support Th17 cell effector function in response to TLR7 ligation, J. Immunol, vol.184, pp.1159-1167, 2010. ,
Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus, Sci. Transl. Med, vol.3, pp.73-93, 2011. ,
Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus, Sci. Transl. Med, vol.3, pp.73-92, 2011. ,
Human inflammatory dendritic cells induce Th17 cell differentiation, Immunity, vol.38, pp.336-348, 2013. ,
IRF4 transcription-factordependent CD103(+)CD11b(+) dendritic cells drive mucosal T helper 17 cell differentiation, Immunity, vol.38, pp.958-969, 2013. ,
IRF4 transcription factor-dependent CD11b(+) dendritic cells in human and mouse control mucosal IL-17 cytokine responses, Immunity, vol.38, pp.970-983, 2013. ,
Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, ROR?t and dectin-2, Nat. Immunol, vol.15, pp.143-151, 2013. ,
Enhanced interferon regulatory factor 3 binding to the interleukin-23p19 promoter correlates with enhanced interleukin-23 expression in systemic lupus erythematosus, Arthritis Rheum, vol.64, pp.1601-1609, 2012. ,
Self double-stranded (ds)DNA induces IL-1? production from human monocytes by activating NLRP3 inflammasome in the presence of anti-dsDNA antibodies, J. Immunol, vol.190, pp.1407-1415, 2013. ,
Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors, Immunity, vol.33, pp.375-386, 2010. ,
Human 6-sulfo LacNAc (slan) dendritic cells have molecular and functional features of an important proinflammatory cell type in lupus erythematosus, J. Autoimmun, vol.40, pp.1-8, 2013. ,
Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses, J. Allergy Clin. Immunol, vol.127, pp.1-9, 2011. ,
Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus, J. Clin. Invest, vol.69, pp.1388-1392, 1982. ,
Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation, Immunity, vol.26, pp.371-381, 2007. ,
cAMP response element modulator ? controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus, Proc. Natl. Acad. Sci. U. S. A, vol.109, pp.16606-16611, 2012. ,
Tsokos, cAMP-responsive element modulator (CREM)? protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus, J. Biol. Chem, vol.286, pp.43437-43446, 2011. ,
Abnormalities of T cell signaling in systemic lupus erythematosus, Arthritis Res. Ther, vol.13, p.207, 2011. ,
Increased expression of SLAM receptors SLAMF3 and SLAMF6 in systemic lupus erythematosus T lymphocytes promotes Th17 differentiation, J. Immunol, vol.188, pp.1206-1212, 2012. ,
Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus, Arthritis Rheum, vol.65, pp.1592-1602, 2013. ,
The role of IL-23/IL-17 axis in lupus nephritis, J. Immunol, vol.183, pp.3160-3169, 2009. ,
Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice, J. Immunol, vol.184, pp.4605-4609, 2010. ,
T cell-specific overexpression of interleukin-27 receptor ? subunit (WSX-1) prevents spontaneous skin inflammation in MRL/lpr mice, Br. J. Dermatol, vol.164, pp.1214-1220, 2011. ,
Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice, Nat. Immunol, vol.9, pp.166-175, 2008. ,
Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway, J. Exp. Med, vol.206, pp.1661-1671, 2009. ,
Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis, Immunity, vol.37, pp.1104-1115, 2012. ,
Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation, Immunity, vol.35, pp.986-996, 2011. ,
Plasticity of Th17 cells in Peyer's patches is responsible for the induction of T cell-dependent IgA responses, Nat. Immunol, vol.14, pp.372-379, 2013. ,
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis, J. Exp. Med, vol.203, pp.2577-2587, 2006. ,
IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A, J. Immunol, vol.186, pp.1495-1502, 2011. ,
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, Lancet, vol.371, issue.1, pp.1665-1674, 2008. ,
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, Lancet, vol.371, issue.2, pp.1675-1684, 2008. ,
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial, Lancet, vol.382, pp.780-789, 2013. ,
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial, Ann. Rheum. Dis, vol.73, pp.990-999, 2014. ,
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS), Ann. Rheum. Dis, vol.73, pp.817-823, 2014. ,
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease, Gastroenterology, vol.135, pp.1130-1141, 2008. ,
Ustekinumab induction and maintenance therapy in refractory Crohn's disease, N. Engl. J. Med, vol.367, pp.1519-1528, 2012. ,
Successful treatment of subacute lupus erythematosus with ustekinumab, Arch. Dermatol, vol.147, pp.896-898, 2011. ,
Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus, Lupus, vol.21, pp.1007-1010, 2012. ,
Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: a case report, Acta Derm. Venereol, vol.93, pp.368-369, 2013. ,
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis, Sci. Transl. Med, vol.2, pp.52-72, 2010. ,
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study, Br. J. Dermatol, vol.168, pp.412-421, 2013. ,
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis, N. Engl. J. Med, vol.366, pp.1190-1199, 2012. ,
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis, N. Engl. J. Med, vol.366, pp.1181-1189, 2012. ,
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial, Lancet, vol.382, pp.1705-1713, 2013. ,
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial, Ann. Rheum. Dis, vol.73, pp.349-356, 2014. ,
How cytokine networks fuel inflammation: interleukin-17 and a tale of two autoimmune diseases, Nat. Med, vol.19, pp.824-825, 2013. ,
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study, Ann. Rheum. Dis, vol.72, pp.863-869, 2013. ,
Phase 2 randomized study of subcutaneous ixekizumab, an Anti-IL-17 monoclonal antibody, in biologic-naïve or TNF-IR patients with rheumatoid arthritis, Arthritis Rheumatol, 2014. ,
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, doubleblind placebo-controlled trial, Gut, vol.61, pp.1693-1700, 2012. ,
Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome, Nat. Rev. Rheumatol, vol.6, pp.529-537, 2010. ,
The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjögren's syndrome: a critical review, J. Autoimmun, vol.51, pp.44-50, 2014. ,
Pathogenic effect of interleukin-17A in induction of Sjögren's syndrome-like disease using adenovirus-mediated gene transfer, Arthritis Res. Ther, vol.12, p.220, 2010. ,